SecBot SecBot

CABA

Cabaletta Bio, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001759138 Biotech & Drug Discovery
$1.11 −0.17 (−13.28%)
Nov 16 4:00 PM ET · prev $1.28
Market cap
$286.9M
Micro cap
Consensus
Buy
81% Buy or better · 16 analysts
Median target
$13.50
+1116% · range $3.00–20.00
1 year
−53.6%
from $2.39 · Nov 17
30 days
−25.0%
from $1.48
52-week range
$1.11–4.15
at the low
Avg volume 20D
4.47M
shares / day
Short interest
38.37M
≈17.8% of shares · −2.3%
Days to cover
8.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
27
analyzed by SecBot
SecBot read BULLISH 13 reports · 90 days
Balance 0 bearish · 2 bullish · 11 neutral oldest → newest, height = score
Avg score ·High conf. 9/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 36 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    13 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.317 → −$0.283 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.3% to 38.37M shares. 8.2 days to cover, ≈17.8% of shares.

  • TrendDOWNTREND

    41% below its 50-day average. New closing low $1.11 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD14,381,113$27.6M
MORGAN STANLEYADD2,351,096$4.5M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,279,377$4.4M
Qube Research & Technologies LtdADD2,106,718$4.0M
FMR LLCDOUBLED1,498,801$2.9M
Nuveen, LLCADD1,030,976$2.0M
TD ASSET MANAGEMENT INCADD651,472$1.3M
MANUFACTURERS LIFE INSURANCE COMPANY, THEDOUBLED385,775$740.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 81% rate it Buy or better
Strong Buy6Buy7Hold3Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +1116%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Citigroup
MAINTAIN
MAINTAINBuy
Sep 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 14, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight

Washington

Corporate Lobbying

5 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 9, 2026
Brun Scott C.
Director
Jun 9, 2026
AWARD22,000 sh
Jun 9, 2026
Bollard Catherine
Director
Jun 9, 2026
AWARD22,000 sh
Jun 9, 2026
HENRIQUES RICHARD C JR
Director
Jun 9, 2026
AWARD22,000 sh
Jun 9, 2026
Simon Mark
Director
Jun 9, 2026
AWARD22,000 sh
Jun 9, 2026
Tomasello Shawn
Director
Jun 9, 2026
AWARD22,000 sh
Mar 2, 2026
Chang David J.
Chief Medical Officer
Mar 2, 2026
AWARD225,000 sh
Mar 2, 2026
Gerard Michael
General Counsel
Mar 2, 2026
AWARD175,000 sh
Mar 2, 2026
Binder Gwendolyn
President, Science & Tech.
Mar 2, 2026
AWARD225,000 sh

Earnings setup

Estimates
−$0.28
EPS estimate, this quarter
+11%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.28-$0.35–-$0.23+9.1%$0.00
Next Q-$0.28-$0.36–-$0.24+5.1%$0.00
Current FY-$1.29-$1.41–-$1.18+5.1%$0.00
Next FY-$1.13-$1.54–-$0.87+5.3%$0.00

Short side

FINRA· Oct 30, 2026
38,369,896
shares short
-2.3%
vs prior settlement
8.2
days to cover
≈17.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Norges Bank filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of 8,663,310 shares…
SC 13G/A · Impact 2/10
Nov 9, 2026 Earnings calendar
CABA Q3 2026 Earnings Before Market Open · 2026-11-09
Nov 8, 2026 Press
Cabaletta Bio presented new Phase 1/2 data at ACR Convergence 2026 showing 100% of dermatomyositis patients maintained…
Impact 6/10
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
14,381,113 shares ($27.6M)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
2,351,096 shares ($4.5M)
Jun 9, 2026 Insider
Brun Scott C. was granted 22,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 9, 2026
Earnings date
CABA Q3 2026 Earnings Before Market Open · 2026-11-09
Nov 8, 2026
FDA
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also…
Nov 5, 2026
Earnings
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis…
Nov 4, 2026
Press release
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on…
Oct 5, 2026
Press release
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on…

SecBot reports

27 filings · 2 press releases · 6 bullish · 3 bearish · 18 neutral
All CABA filing & press-release reports (29)